Options for Treatment of Lung Cancer with Irinotecan

Publisher： Karger

E-ISSN： 2296-5262|23|4|34-36

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.4, 2000-05, pp. : 34-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 280-284

Karger

Access to resources Recommend Favorite

Combination of Cisplatin, Ifosfamide, and Irinotecan with rhG-CSF Support for the Treatment of Refractory or Relapsed Small-Cell Lung Cancer

By  

Oncology, Vol. 59, Iss. 2, 2000-08 ,pp. : 105-109

Karger

Access to resources Recommend Favorite

ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2392-2402

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Role of Irinotecan in Non-Small Cell and Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 6, 2004-11 ,pp. : 25-27

Karger

Access to resources Recommend Favorite

Stratified Treatment in Lung Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 12, 2016-11 ,pp. : 760-766

Karger

Access to resources Recommend Favorite